New depression drug GM-2505 enters Mid-Stage trial
NCT ID NCT06236880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called GM-2505 in people with major depressive disorder. Participants receive two doses of the drug two weeks apart. The study has three parts: one for people not on antidepressants, one for those partially responding to current treatment, and one to confirm earlier findings. The main goal is to check safety and tolerability, with early signs of antidepressant effect also measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GM-2505 (an experimental drug given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for people with major depressive disorder who are not responding well to current antidepressants.
What could go wrong
This is an early Phase 2a study with only 124 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MAC Clinical Research
RECRUITINGManchester, United Kingdom
Contact